Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud
Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA.
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<